218 related articles for article (PubMed ID: 16807454)
1. Role of gemcitabine in ovarian cancer treatment.
Lorusso D; Di Stefano A; Fanfani F; Scambia G
Ann Oncol; 2006 May; 17 Suppl 5():v188-94. PubMed ID: 16807454
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine in epithelial ovarian cancer treatment: current role and future perspectives.
Lorusso D; Ferrandina G; Fruscella E; Marini L; Adamo V; Scambia G
Int J Gynecol Cancer; 2005; 15(6):1002-13. PubMed ID: 16343176
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine in ovarian cancer.
Orlando M; Mandachain M
Semin Oncol; 2001 Jun; 28(3 Suppl 10):62-9. PubMed ID: 11510036
[TBL] [Abstract][Full Text] [Related]
4. Management of platinum-sensitive recurrent ovarian cancer.
Pfisterer J; Ledermann JA
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S12-6. PubMed ID: 16716798
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma.
Kose MF; Meydanli MM; Tulunay G
Expert Rev Anticancer Ther; 2006 Mar; 6(3):437-43. PubMed ID: 16503860
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine and vinorelbine combination in platinum-sensitive recurrent ovarian cancer.
Ferrero A; Logrippo V; Spanu PG; Fuso L; Perotto S; Daniele A; Zola P
Int J Gynecol Cancer; 2009 Dec; 19(9):1529-34. PubMed ID: 19955931
[TBL] [Abstract][Full Text] [Related]
7. The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
Safra T; Asna N; Veizman A; Shpigel S; Matcejevsky D; Inbar M; Grisaru D
Anticancer Drugs; 2014 Mar; 25(3):340-5. PubMed ID: 24185383
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study.
Harnett P; Buck M; Beale P; Goldrick A; Allan S; Fitzharris B; De Souza P; Links M; Kalimi G; Davies T; Stuart-Harris R
Int J Gynecol Cancer; 2007; 17(2):359-66. PubMed ID: 17362313
[TBL] [Abstract][Full Text] [Related]
9. Optimizing gemcitabine regimens in ovarian cancer.
Pecorelli S; Pasinetti B; Tisi G; Odicino F
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S17-25. PubMed ID: 16716799
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer.
Friedlander M; Buck M; Wyld D; Findlay M; Fitzharris B; De Souza P; Davies T; Kalimi G; Allan S; Perez D; Harnett P
Int J Gynecol Cancer; 2007; 17(2):350-8. PubMed ID: 17362312
[TBL] [Abstract][Full Text] [Related]
11. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.
Monk BJ; Coleman RL
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S63-7. PubMed ID: 19955917
[TBL] [Abstract][Full Text] [Related]
12. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.
du Bois A; Herrstedt J; Hardy-Bessard AC; Müller HH; Harter P; Kristensen G; Joly F; Huober J; Avall-Lundqvist E; Weber B; Kurzeder C; Jelic S; Pujade-Lauraine E; Burges A; Pfisterer J; Gropp M; Staehle A; Wimberger P; Jackisch C; Sehouli J
J Clin Oncol; 2010 Sep; 28(27):4162-9. PubMed ID: 20733132
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer.
Pfisterer J; Vergote I; Du Bois A; Eisenhauer E; ; ;
Int J Gynecol Cancer; 2005; 15 Suppl 1():36-41. PubMed ID: 15839957
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
Pfisterer J; Plante M; Vergote I; du Bois A; Hirte H; Lacave AJ; Wagner U; Stähle A; Stuart G; Kimmig R; Olbricht S; Le T; Emerich J; Kuhn W; Bentley J; Jackisch C; Lück HJ; Rochon J; Zimmermann AH; Eisenhauer E; ; ;
J Clin Oncol; 2006 Oct; 24(29):4699-707. PubMed ID: 16966687
[TBL] [Abstract][Full Text] [Related]
15. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
16. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
17. [Gemcitabine based combination chemotherapy, a new salvage regimen for recurrent platinum resistant epithelial ovarian cancer].
Chu P; Lu CH; Sheng XG; Zhou CX; Li DP; DU XL; Liu NF
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):808-12. PubMed ID: 21211276
[TBL] [Abstract][Full Text] [Related]
18. Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma.
Villella J; Marchetti D; Odunsi K; Rodabaugh K; Driscoll DL; Lele S
Gynecol Oncol; 2004 Dec; 95(3):539-45. PubMed ID: 15581960
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.
Sufliarsky J; Chovanec J; Svetlovska D; Minarik T; Packan T; Kroslakova D; Lalabova R; Helpianska L; Horvathova D; Sevcik L; Spacek J; Laluha A; Tkacova V; Malec V; Rakicka G; Magdin D; Jancokova I; Dorr A; Stresko M; Habetinek V; Koza I
Neoplasma; 2009; 56(4):291-7. PubMed ID: 19473054
[TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy for recurrent ovarian cancer].
Maejima A; Katsumata N
Nihon Rinsho; 2012 Jun; 70 Suppl 4():605-9. PubMed ID: 23156318
[No Abstract] [Full Text] [Related]
[Next] [New Search]
